Tools
Stock profile

BIO-TECHNE Corp (TECH)

TECH · Latest close $72.75 as of Nov 18, 2026 · 13F data as of Jun 30, 2026 (2026 Q2)
Latest close
$72.75
As of Nov 18, 2026
Tracked funds holding
5 of 149
2026 Q2 13F filings
Opened / added
0 / 0
vs previous quarter
Trimmed / exited
5
vs previous quarter

BIO-TECHNE Corp (TECH) is held by 5 of 149 tracked super-investor funds (144 filed in Q2) in 2026 Q2 13F filings, with 5 funds trimming or exiting versus the previous quarter. 0 members of Congress reported 0 purchases vs 1 sale. Latest close $72.75 as of Nov 18, 2026.

Data as of Nov 18, 2026 (prices) · 2026 Q2 13F filings (quarter ended Jun 30, 2026) · Latest Form 4: none in the last 90 days · Congress to Nov 16, 2026.

Funds
2026 Q2 13F
Congress
0 buys vs 1 sale
Fundamentals
Revenue · FY2026
Red flags
none flagged
Short interest
as of Oct 15, 2026
Holdings · Charts · All institutions · Fundamentals · Short interest · Fails to deliver · Insider trading · 5% holders · Planned sales · Politician trading · Committee jurisdiction · Government relations · Screens & lenses · Signal record · Related stocks · Recent 8-K

Funds holding this

Ruane Cunniff LP · Weitz Investment Management · Mairs & Power Funds — 5 tracked funds hold TECH. See all holders.

Insider and Congress activity

0 members of Congress reported buying (0 purchases vs 1 sale). Politician trading

Often held alongside

ENTEGRIS INC (ENTG) · Ferguson Enterprises Inc. /DE/ (FERG) · ANALOG DEVICES INC (ADI) · MICRON TECHNOLOGY INC (MU) · CAPITAL ONE FINANCIAL CORP (COF) — stocks the same funds also hold. See all related stocks.

Super-investor holdings · 2026 Q2

FundPortfolio weightSharesChange vs prev. quarter
Ruane Cunniff LP3.68%3,348,841TRIMMED (-1.3%) Q3 filed Nov 16
Weitz Investment Management2.66%543,200TRIMMED (-16.8%) Q3 filed Nov 12
Mairs & Power Funds1.75%2,700,698TRIMMED (-1.8%) Q3 filed Nov 16
Maverick Capital0.96%1,535,610TRIMMED (-67.6%) Q3 filed Nov 16
Durable Capital Partners0.34%501,963TRIMMED (-88.7%) Q3 filed Nov 16

Source: SEC Form 13F filings, quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. Fund counts aggregate every share class mapped to this ticker.

Price change since quarter-end: +2.3% from the close on the first trading day after the quarter ended (Jul 1, 2026) to the latest close (Nov 17, 2026). 13F does not report purchase prices — this is the price change since the quarter-end close, not a gain on any fund’s actual purchase.

Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.

Charts

78.7541.882024-11-192026-11-18

Closing prices (unadjusted for dividends), last 2 years — 501 trading days to Nov 18, 2026. Dashed lines mark 13F filing deadlines. Source: Yahoo Finance daily bars.

All institutions · Form 13F

Institutions holding591 of 8,857 filers
Long-only filers among them590
Change vs 2026 Q1+20 net · 550 entered · 530 exited
Shares reported, all filers172,222,861
Reported value, all filers$12.0B

Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).

Company fundamentals

ExchangeNasdaq
IndustryBiological Products, (No Diagnostic Substances) (SIC 2836)
Revenue · FY2026$1.2B
Net income · FY2026$181.9M
Total assets · FY2026$2.6B
Shares outstanding157,055,564
Market cap (at latest close)$11.4B

Source: SEC EDGAR company filings (submissions and company facts), collected Oct 30, 2026. Shares outstanding as reported Oct 9, 2026.

Short interest

Shares short · Oct 15, 20267,552,208
Share of shares outstanding4.81%
Days to cover2.88

Shares short at recent settlements — Jul 31, 2026: 9.3M · Aug 14, 2026: 6.5M · Aug 31, 2026: 5.9M · Sep 15, 2026: 6.6M · Sep 30, 2026: 7.4M · Oct 15, 2026: 7.6M.

Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Oct 9, 2026.

Fails to deliver

Shares failed to deliver · Oct 14, 20260
Share of shares outstanding0.00%
Fails as a share of short interest · Oct 15, 20260.0%

Fails to deliver at recent settlements — Jul 31, 2026: 0 · Aug 14, 2026: 0 · Aug 31, 2026: 185 · Sep 15, 2026: 0 · Sep 30, 2026: 0 · Oct 14, 2026: 0.

Source: SEC Fails-to-Deliver data (semi-monthly files, published about two weeks after each settlement date). Each figure is the balance of shares not yet delivered on that date; a stock absent from that date’s file counts as zero. See our research on whether fails to deliver predict returns. Shares outstanding from SEC filings as of Oct 9, 2026.

Insider trading · Form 4

Data unavailable — no Form 4 transactions for this ticker were parsed in the last 90 days.

Planned sales · Form 144

FiledSellerRoleShares to sellMarket valueApprox. sale dateSource
May 8, 2026JOSHUA MOLHODirector6,636$320.4KMay 8, 2026SEC filing
Feb 17, 2026JOSHUA MOLHODirector1,976$116.8KFeb 17, 2026SEC filing
Aug 25, 2025ROELAND NUSSEDirector17,040$960.4KAug 25, 2025SEC filing
Aug 25, 2025ROBERT V. BAUMGARTNER4731 BONITA BAY BOULEVARDDirector17,040$957.8KAug 25, 2025SEC filing
Jun 9, 2025JOSHUA MOLHOOfficer1,280$63.7KJun 9, 2025SEC filing
Feb 14, 2025JOSHUA MOLHODomestic Partner of Director1,860$122.7KFeb 14, 2025SEC filing
Jan 27, 2025KIM KELDERMANDirector, Officer13,392$1.0MJan 27, 2025SEC filing
Aug 8, 2024ROBERT V. BAUMGARTNERDirector16,000$1.2MAug 8, 2024SEC filing
May 14, 2024JOHN L HIGGINSDirector4,000$335.4KMay 14, 2024SEC filing
Mar 7, 2024Nusse RoelandDirector10,400$800.6KMar 7, 2024SEC filing

A Form 144 notice is a planned sale, not a completed sale. Most recent first. Source: SEC Form 144 filings, 63,013 notices from Apr 13, 2023 to Oct 9, 2026.

5% holders · Schedule 13D/G

FiledFilerFormShares% ownedEvent dateSource
Aug 6, 2026FMR LLCSC 13G/A12,754,783.648.1%Jun 30, 2026SEC filing
May 6, 2026FMR LLCSC 13G7,859,928.335.0%Mar 31, 2026SEC filing
Apr 29, 2026Vanguard Capital ManagementSC 13G11,559,5717.4%Mar 31, 2026SEC filing
Mar 26, 2026The Vanguard GroupSC 13G/A00.0%Mar 13, 2026SEC filing
Nov 14, 2025T. Rowe Price Associates, Inc.SC 13G/A3,350,8182.2%Sep 30, 2025SEC filing
Aug 14, 2025T. Rowe Price Associates, Inc.SC 13G/A8,848,1505.6%Jun 30, 2025SEC filing
Jul 16, 2025BlackRock, Inc.SC 13G/A11,011,5567.0%Jun 30, 2025SEC filing
May 14, 2025T. Rowe Price Associates, Inc.SC 13G/A11,383,6077.2%Mar 31, 2025SEC filing

One filing is one row; a filing may list several reporters and the first is shown. Figures are as filed, including amendments that report zero shares after a transfer. Source: SEC Schedule 13D/G filings, 57,443 filings parsed to Oct 2, 2026.

Politician trading · U.S. Congress

0 members of Congress reported buying (0 purchases vs 1 sale).

Source: U.S. House Clerk and U.S. Senate eFD STOCK Act periodic transaction reports, as of Nov 16, 2026. Reported amounts are ranges, and reports can arrive up to 45 days after the trade.

Recent activity by member

MemberChamberPartyBuysSellsLatestAmount range
Delaney, April McClainHouseD01Apr 8, 2026$1,001 - $15,000

Member-level activity in the current window, most recent first (House data to Nov 16, 2026, Senate to Oct 1, 2026). House reports arrive as PDFs without transaction-level rows in the current corpus, so this table shows per-member totals, not individual trades; the member page lists the underlying filings. Senate rows link the same way — the member page carries the eFD filing links.

Committee jurisdiction

Industry: Biological Products, (No Diagnostic Substances) (SIC 2836). Standing committees with jurisdiction over this industry: Senate Committee on Health, Education, Labor, and Pensions, House Committee on Energy and Commerce.

None of the members who traded this stock in the current window sit on these committees.

Assignments are the current (119th Congress) rosters. A trade made in an earlier Congress may have been made under a different assignment. Jurisdiction is by industry (SEC SIC code), not by anything the company said or did. Same rule as our committee-jurisdiction study.

Government relations

Lobbying: 18 Lobbying Disclosure Act filings named this company as client, 2020–2026; most common issues: Agriculture (6), Health Issues (5), Budget/Appropriations (1).

Federal contracts: $9.3M in obligated amounts, fiscal years 2021–2026.

Fiscal yearObligated amount
FY2021$2.7M
FY2022$1.1M
FY2023$2.2M
FY2024$1.6M
FY2025$714.3K
FY2026$977.5K

Largest awards collected

Award IDAgencyAmountStart
75N98026P01060Department of Health and Human Services$399.8KJul 20, 2026
75F40121P00040Department of Health and Human Services$233.5KMar 8, 2021
12805B23P0080Department of Agriculture$169.3KFeb 7, 2023
36C24E24P0011Department of Veterans Affairs$156.1KFeb 12, 2024
HHSN261201800146PDepartment of Health and Human Services$123.7KFeb 1, 2018

Lobbying filings are matched by company core name; a filing can match more than one ticker. Contract amounts are obligated amounts (money committed, not money spent), matched by recipient name — contracts under a subsidiary’s name can be missed. Sources: Senate Lobbying Disclosure Act filings; USAspending.gov. See Methodology.

Screens & lenses

Financial Screens

· Graham — Sound finances and a long run of profits

· Piotroski — Financial health improved over the past year

· Earnings Quality (Cash Conversion) — Profits that actually come back as cash

· Earnings Stability — Small earnings swings and almost no loss years

Chart Signals

· Monthly Uptrend — Price above its 12-month moving average

· Top Relative Strength — Top 20% of the universe by 6-month return

Key figures

· Graham — Current ratio: 4.55 · Straight profitable years: 18 · Debt ratio: — · Latest net income: $181.9M

· Piotroski — F-score: 7 · Return on assets: 7.0% · Operating cash flow: $292.1M

· Earnings Quality (Cash Conversion) — Cash conversion (3-yr avg): 2.43 · Operating cash flow: $292.1M · Net income: $181.9M

· Earnings Stability — Earnings variation (CV): 0.44 · Loss years (of 10): 0 · Latest net income: $181.9M

Financial screens are computed from SEC company financial statements; red-flag models are screens, not verdicts — see Methodology.

Signal record

13F signal (2021 Q3 – 2026 Q1)EventsWin rateAvg returnSPYExcess
Heavy accumulation — 3+ tracked funds increased together425.0%+8.9%+5.2%+3.7%
Share count tripled (3x)20.0%-12.4%+0.2%-12.6%

Measured from SEC 13F filings: entry at the close on the first trading day after each quarter’s filing deadline, exit one quarter later on the same rule, dividend-adjusted closes. Past records do not guarantee future results — see Track Record and Methodology.

Also held by the tracked funds that hold TECH — ranked by lift, the co-holding pattern described in Methodology: ENTEGRIS INC (ENTG) · Ferguson Enterprises Inc. /DE/ (FERG) · ANALOG DEVICES INC (ADI) · MICRON TECHNOLOGY INC (MU) · CAPITAL ONE FINANCIAL CORP (COF) · TEXAS INSTRUMENTS INC (TXN).

Recent 8-K filings

FiledItemsSource
Nov 4, 20268.01 Other Events · 9.01 Financial Statements and ExhibitsSEC filing
Sep 23, 20265.07 Submission of Matters to a Vote of Security Holders · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and ExhibitsSEC filing
Sep 14, 20268.01 Other EventsSEC filing

Source: SEC EDGAR Form 8-K filings, latest first. Amendments (Form 8-K/A) are labeled as such. Item labels are the SEC's item titles; a filing can carry several items. Item 5.02 covers both departures and appointments, which this index does not distinguish.

Related

ENTEGRIS INC (ENTG) · Track Record: how the signals scored · Practice timing on TECH

One email a week: the week’s new filings and research. Subscribe free

← TEAM  ·  TECK →

Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.